Hepatitis C virus NS3/4A protease inhibitors

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 3, 2008, Pages 157-167

  López Labrador, Francesc Xavier ^a,b,c  

^a CSISP   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Antivirals; HCV; Therapy; Viral resistance

Indexed keywords

ACH 806; BI 201335; BOCEPREVIR; CILUPREVIR; ITMN 191; MK 7009; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SCH 446211; SCH 6; SERINE PROTEINASE INHIBITOR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 58149131455     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108786242369     Document Type: Review

References (80)

1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-678.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
3. Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007; 59: 1222-1241.
4. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687.
5. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-456.
6. Domingo E, Menendez-Arias L, Quinones-Mateu ME, et al. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 1997; 48: 99-128.
7. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-3229.
8. Blight KJ, Kolykhalov AA, Reed KE, Agapov EV, Rice CM. Molecular virology of hepatitis C virus: An update with respect to potential antiviral targets. Antivir Ther 1998; 3: 71-81.
9. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
10. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
11. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Nat Acad Sci 2005; 102: 9294-9299.
12. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Nat Acad Sci USA 2006; 103: 2310-2315.
13. Scheel TKH, Gottwein JM, Jensen TB, et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Nat Acad Sci USA 2008; 105: 997-1002.
14. Gottwein JM, Scheel TKH, Hoegh AM, et al. Robust Hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/ JFH1) Viruses. Gastroenterology 2007; 133: 1614-1626.
15. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
16. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993; 67: 2832-2843.
17. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102: 2992-2997.
18. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-189.
19. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 1347-1355.
20. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 3-16.
21. Lawitz E, Rodriguez-Torres, Muir, et al. 28 Days of the Hepatitis C Protease Inhibitor VX-950, in combination with PEG-Interferon-ALFA-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology 2006; 131: 950-951.
22. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50: 1013-1020.
23. Bogen SL, Arasappan A, Bennett F, et al. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 2006; 49: 2750-2757.
24. Liu R, Abid K, Pichardo J, et al. in vitro Antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother 2007; 59: 51-58.
25. Prongay AJ, Guo Z, Yao N, et al. Discovery of the HCV NS3/4A protease inhibitor [[(1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3- dioxopropyl]-3-2(S)-[(1,1 dimethylethyl)amino]carbonyl]amino]-3, 3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)- carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization. J Med Chem 2007; 50: 2310-2318.
26. Seiwert SD, Andrews SW, Tan H, et al. 750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development. J Hepatol 2006; 44: S278.
27. Reesink HR, Verloes K, Abou Farha A, et al. Safety of the HCV protease inhibitor TMC45350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: A phase I study. 43rd Annual Meeting of the European Association for the study of the liver. Milan, Italy, April 23-27 2008. J Hepatol 2008; 48 (S2): S28.
28. Ludmerer S, Graham D, Handt L, et al. Evaluation of MK-7009, a novel macrocyclic inhibitor of NS3/4A Protease, in the Chimpanzee Model of chonic Hepatitis C Virus Infection. The twenty-first international conference on antiviral research, Montreal, Quebec, Canada. April 13-17, 2008. Antiviral Research 2008; 78: A23
29. Achillion Pharmaceuticals. Gilead and Achillion announce positive antiviral activity of NS4A antagonist in HCV, but discontinue GS 9132 (ACH-806) development. Press release 2007, accessed Jun 2008: http://achillion.com
30. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
31. Kieffer T, Zhou Y, Zhang E, et al. Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1-infected patients. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Hepatology 2007; 46 (suppl 1): 862A.
32. McHutchison JG, Everson GT, Gordon S, et al. Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon-alfa-2a and ribavirin in previously untreated subjects with hepatitis C. Annual meeting of the european association for the study of the liver 2007, Barcelona, Spain. J Hepatol 2007; 46: S296.
33. McHutchison JG, Everson GT, Gordon SC, et al. PROVE1 Study: results from a phase 2 study of telaprevir with peginterferon plus ribavirin in treatment-naIve subjects with hepatitis C. 43rd Annual Meeting of the European Association For The Study Of The Liver, Milan, Italy. April 23-27, 2008. J Hepatol 2008; 48 (S2): S4.
34. Dusheiko GM, Hezode C, Pol S, et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE2 study. 43rd Annual Meeting of the European Association for The study of the liver. Milan, Italy. April 23-27,2008. J Hepatol 2008; 48 (S2): S26.
35. Zeuzem S, Sarrazin C, Rouzier R, et al. Antiviral activity of SCH 503034, A HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-alpha). Annual Meeting of the American Association for the Study of Liver Diseases, 2005. Hepatology 2005; 42: 233A-234A.
36. Kwo P, Lawitz E, McCone J, et al. Interim results from HCV SPRINT-1 RVR/SVR from phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. 43rd Annual Meeting of the European Association for The study of the liver. Milan, Italy. April 23-27, 2008. J Hepatol 2008; 48 (S2): S372.
37. Tan H, Seiwert SD, Blatt LM. in vitro Synergistic antiviral activity of ITMN-191, an orally active inhibitor of the hepatitis C virus (HCV) NS3/4A protease, in combination with PEG-interferon alfa-2a. Hepatology 2006; 44 (S1): 534A.
38. Ravi RPT, Stevens S, Stoycheva A, et al. Genotype coverage of the hcv ns3/4a protease inhibitor ITMN-191 (r7227): Biochemical data reveals potent inhibition and slow dissociation with genotype 1-6 proteases. 58th Annual Meeting of the American Association for the Study of Liver Diseases. 2007, Boston, Nov. 2-6. Hepatology 2007; 46 (S1): 855A.
39. van't Klooster GAE, Vanwelkenhuysen I, Hooijmaijers R, et al. Once-Daily regimes of the NS3/4A-protease inhibitor TMC435350 are predicted to provide therapeutic exposure in plasma and liver. 43rd Annual Meeting of the European Association for the study of the liver. Milan, Italy, April 23-27 2008. J Hepatol 2008; 48 (S2): S321.
40. Yang W, Zhao Y, Fabrycki J, et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother 2008; 52: 2043-2052.
41. Pottage JCJ, Lawitz E, Mazur D, et al. Short-term antiviral activity and safety of ACH-806 (GS-9132), an NS4A antagonist, in HCV genotype 1 infected individuals. 42nd Annual Meeting of the European Association for the study of the liver, Barcelona, Spain, 2007. J Hepatol 2007; 46 (Suppl 1): A783.
42. Condra JH, Schleif WA, Blahy OM, et al. in vivo Emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-571.
43. Trozzi C, Bartholomew L, Ceccacci A, et al. in vitro Selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003; 77: 3669-3679.
44. Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48: 2260-2266.
45. Lin C, Lin K, Luong YP, et al. in vitro Resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-17514.
46. Lin C, Gates CA, Rao BG, et al. in vitro Studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280: 36784-36791.
47. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005; 49: 4305-4314.
48. Yi M, Tong X, Skelton A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2005; 281: 8205-8215.
49. Seiwert S, Hong J, Lim S, Tan H, Kossen K, Blatt L. Rev Antiviral Ther 2007; 1: 56
50. Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 Variants: Sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 22619-22628.
51. Zeuzem S, Sarrazin C, Wagner F, et al. The HCV NS3 protease inhibitor SCH 503034 in combination with Peg-IFN alpha-2b in the treatment of HCV-1 Peg-IFN alpha-2b nonresponders: antiviral activity and HCV variant analysis. Annual Meeting of the European Association for the study of the liver 2006. J Hepatol 2006; 44 (Suppl 2): S35.
52. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
53. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 43: 631-639.
54. Schiff E, Poordad F, Jacobson I, et al. Boceprevir combination theraphy in null responders: response dependent on interferon responsiveness. 43rd Annual Meeting of the European Association for the study of the liver, Milan, Italy, April 23-27 2008. J Hepatol 2008; 48 (S2): S46.
55. Bartels DJ, Zhou Y, Zhang E, et al. Natural prevalence of HCV variants with decreased susceptibility to protease inhibitors in treatment-naive subjects. 43rd Annual Meeting of the European Association for the study of the liver, Milan, Italy, April 23-27 2008. J Hepatol 2008; 48 (S2): S316.
56. Susser S, Welker MW, Zettler M, et al. Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir (SCH203034). 43rd Annual Meeting of the European Association for the study of the liver, Milan, Italy, April 23-27 2008. J Hepatol 2008; 48 (S2): S29.
57. Welsch C, Domingues FS, Antes I, et al. Molecular basis for VX-950 resistance. 42rd Annual Meeting of the European Association for the study of the liver, Barcelona, Spain, 2007. J Hepatol 2007; 46 (S2): S30.
58. Njoroge, G.F., Arasappan, A., Venkatraman, S., Bogen, S.L., Chen, X.K., Bennett, F.: US20070232549 (2007).
59. Farmer, L.J., Perni, R.B., Pitlik, J., Van, D.: US20080045480 (2008).
60. Niu, D., Moore, J.D., Liu, D., Gai, Y., Chen, Z., Or, Y.S., Wang, Z.: US20080039470 (2008).
61. Gai, Y., Niu, D., Or, Y.S., Wang, Z.: US20080032936 (2008).
62. Moore, J.D., Niu, D., Xu, G., Liu, D., Or, Y.S., Waug, Z.: US20080039375 (2008).
63. Sun, Y., Or, Y.S., Wang, Z.: US20080038225 (2008).
64. Brandl, T.B., Britt, S.D. Cottens, S., Ehrhardt, C., Fu, J., Karur, H., Li, H., Lu, P., Parker, D.T., Patane, M., Ratetich, B., Raman, P., Randl, S.A., Rigollier, P., Seepersaud, M., Simic, O., Tichkule, R.B., Zhu, Y.: US20080045530 (2008).
65. Ghosal, A., Kishnani, N.S., Alton, K.B., White, R.E.: US20070232527 (2007).
66. Ralston, II R.O., Strizki, J.M., Vlach, J., Gupta, S.K., O'mara, Jr. E.M., Ghosal, A., Treitel, M.A., Mcleod. J.F., White, R.E.: US20070287664 (2007).
67. Seiwert, S., Beigelman, L., Blatt, L.M., Kercher, T., Kennedy, A.L., Andrews, S.W.: US20080019942 (2008).
68. Malcolm, B.A., Cho, W.-P., Alton, K.B., Qiu, Z., Wan, J., Monteith, D.: US20070237818 (2007).
69. Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004; 48: 4784-4792.
70. McHutchison JG. 28 Days of the hepatitis C protease inhibitor VX-950, in combination with PEG-Interferon-ALFA-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Digestive Diseases Week 2006. Gastroenterology 2006; 131: 950.
71. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-1278.
72. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172.
73. Foy E, Li K, Sumpter R, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 2005; 102: 2986-2991.
74. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38.
75. Emini, E.A., Flint, M.J., Howe, A.Y.M., Malcolm, B.A., Mullen, S., Ralston, II R.O., Tong, X.: US20070224167 (2007).
76. Holland-Staley CA, Kovari LC, Golenberg EM, Pobursky KJ, Mayers DL. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 2002; 147: 1385-1406.
77. Lodrini S, Bagaglio S, Canducci F, et al. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J Biol Regul Homeost Agents 2003; 17: 198-204.
78. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol 2005; 75: 528-537.
79. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85: 3173-3188.
80. López-Labrador FX, Moya A, González-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antiviral Therapy 2008; 13: 481-494.